Bayer (BAYGn.DE) said it had received a warning letter from the U.S. Food and Drug Administration over how it handled production of some drugs at its Leverkusen, Germany headquarters. The German drugmaker, which is taking over U.S. seed maker Monsanto (MON.N), is addressing the FDA's complaints regarding manufacturing practices, which stem from a routine inspection in January, Bayer said. "We expect temporary supply limitations affecting our mature product portfolio," though distribution from the Leverkusen supply centre would continue, Bayer said.

Bayer said it had received a warning letter from the U.S. Food and Drug Administration over how it handled production of some drugs at its Leverkusen, Germany headquarters. The German drugmaker, which is taking over U.S. seed maker Monsanto, is addressing the FDA's complaints regarding manufacturing practices, which stem from a routine inspection in January, Bayer said. "We expect temporary supply limitations affecting our mature product portfolio," though distribution from the Leverkusen supply centre would continue, Bayer said.

FRANKFURT/MOSCOW (Reuters) - Bayer has taken Russia's antitrust regulator to court over the watchdog's investigation into the company's planned takeover of Monsanto, a further hiccup in the $64 billion deal amid intense antitrust scrutiny. A Bayer spokesman said the German company was petitioning the court in Russia to be given more time to discuss demands made by the regulator about the deal, which would create the world's largest seeds and pesticides company. Bayer made a decision to bring the case to court in order to safeguard its juridical rights," Bayer said in a written statement.

FRANKFURT/MOSCOW (Reuters) - Bayer (BAYGn.DE) has taken Russia's antitrust regulator to court over the watchdog's investigation into the company's planned takeover of Monsanto (MON.N), a further hiccup in the $64 billion deal amid intense antitrust scrutiny. A Bayer spokesman said the German company was petitioning the court in Russia to be given more time to discuss demands made by the regulator about the deal, which would create the world's largest seeds and pesticides company. Bayer made a decision to bring the case to court in order to safeguard its juridical rights," Bayer said in a written statement.

German's Bayer has taken Russia's Federal Anti-Monopoly Service to court in relation to Bayer's planned deal with U.S. seed-maker Monsanto , the RIA news agency quoted the Russian watchdog as saying on ...

Bayer needs to ensure that a merger with rival Monsanto does not stifle competition in digital farming, the European Union's Competition Commissioner Margrethe Verstager told a German newspaper on Saturday. Bayer's $63.5 billion takeover of U.S. Monsanto, announced in 2016, is set to create the world's largest seeds and pesticides company.

BRUSSELS/FRANKFURT, Feb 8 (Reuters) - Bayer plans to sell its global vegetable seeds business and allow BASF exclusive access to its digital farming data in an effort to address EU antitrust concerns over its $63.5 billion purchase of Monsanto, three people close to the matter said on Thursday. The German drug and crop chemicals maker submitted its offer last week after the European Commission said the deal could reduce competition in pesticides, seeds and plant traits such as herbicide tolerance and insect resistance.

Brazilian antitrust agency Cade on Wednesday approved Bayer AG's proposed takeover of U.S. seeds company Monsanto Co without requiring further asset sales beyond a global proposal announced last October. Cade's commissioners voted 4-2 in favor of the tie-up under an agreement, negotiated between the companies and global antitrust agencies, that included the sale of several of Bayer's assets to BASF SE. Approval of the transaction in Brazil, a powerhouse producer of grains and other agricultural commodities, clears a crucial hurdle for the deal, which the companies initially aimed to have approved by the end of 2017.

Brazilian antitrust agency Cade on Wednesday approved Bayer AG's (BAYGn.DE) proposed takeover of U.S. seeds company Monsanto Co (MON.N) without requiring further asset sales beyond a global proposal announced last October. Cade's commissioners voted 4-2 in favor of the tie-up under an agreement, negotiated between the companies and global antitrust agencies, that included the sale of several of Bayer's assets to BASF SE (BASFn.DE). Approval of the transaction in Brazil, a powerhouse producer of grains and other agricultural commodities, clears a crucial hurdle for the deal, which the companies initially aimed to have approved by the end of 2017.

BRUSSELS/FRANKFURT (Reuters) - Bayer has offered to sell seeds and pesticides businesses to try to address EU competition concerns over its $63.5 billion (£45.3 billion) bid for U.S. rival Monsanto. The proposed remedies "are very significant and we are confident they fully address the European Commission's concerns," the German company said in a statement on Monday. The European Commission extended the deadline for its decision on the deal to April 5 from March 12.

BRUSSELS/FRANKFURT, Feb 5 (Reuters) - Bayer has offered to sell seeds and pesticides businesses to try to address EU competition concerns over its $63.5 billion bid for U.S. rival Monsanto. The proposed remedies "are very significant and we are confident they fully address the European Commission's concerns," the German company said in a statement on Monday. The European Commission extended the deadline for its decision on the deal to April 5 from March 12.

Crispr Therapeutics’ largest shareholder just invested another $12 million in the Swiss developer of gene-based medicines. Bayer disclosed that on Jan. 5 a subsidiary bought another 527,500 shares of Crispr (CRSP) for $22.75 each in a public offering. Bayer’s total ownership now stands at 5.71 million shares.

FRANKFURT/BRUSSELS, Jan 29 (Reuters) - Bayer's quest to win regulatory approval for its planned takeover of Monsanto ran into further delays on Monday as European Union antitrust investigators extended their investigation by five working days until March 12. The EU did not state a reason for the extension to March 12 to deliver its verdict on the merger, which effectively gives Bayer a new deadline at midnight Feb. 5 to propose concessions such as asset sales. A Bayer spokesman declined to comment, beyond confirming the EU's statement.

WINNIPEG, Manitoba/CHICAGO (Reuters) - Monsanto Co is facing major threats to its historic dominance of seed and herbicide technology for the $40 billion U.S. soybean market. Rivals BASF SE and DowDuPont are preparing to push their own varieties of genetically modified soybeans. At stake is control over seed supply for the next generation of farmers producing the most valuable U.S. agricultural export.

WINNIPEG, Manitoba/CHICAGO, Jan 24 (Reuters) - Monsanto Co is facing major threats to its historic dominance of seed and herbicide technology for the $40 billion U.S. soybean market. Rivals BASF SE and DowDuPont are preparing to push their own varieties of genetically modified soybeans. The market has opened up as Monsanto's Roundup Ready line of seeds - engineered to tolerate the weed killer glyphosate - has lost effectiveness as weeds develop their own tolerance to the chemical.

Bayer (BAYGn.DE), the drug company that is buying seed maker Monsanto (MON.N), has raised 1.8 billion euros (1.59 billion pounds) from selling a 10.4 percent stake in Covestro (1COV.DE), nearing a complete divestment from the plastics company. Germany's Bayer in October hinted it would need less cash from shareholders than initially expected to fund the Monsanto deal, worth $63.5 billion including debt, partly because of windfalls from selling down its Covestro holding. Bayer sold 21 million Covestro shares for 86.25 euros apiece overnight, cutting its stake to 14.2 percent, Bayer said on Thursday.

Judge Michael Erdos, in the Philadelphia County Court of Common Pleas, ruled following a hearing on the drugmakers' motion to reverse the December verdict, which was their first trial loss in litigation over the blood thinner, the companies said. J&J's Janssen Pharmaceuticals Inc unit and Bayer, which jointly developed Xarelto, in separate statements welcomed the decision and said they will continue to defend against the allegations in related litigation.

The outlook makes the world's biggest seed company the latest agribusiness to detail ongoing pressures from large crop inventories that are weighing on commodity prices following four years of bumper harvests. Monsanto, which is being acquired by Bayer AG (BAYGn.DE), does not have "great hope for significant price improvement" for its U.S. corn seeds, Chief Executive Hugh Grant told analysts on a conference call. "It is a tough year, so everybody is fighting for the last acres," Grant said.

Monsanto anticipates reaping bigger profits this year from its flagship weed killer. The maker of Roundup herbicide said that higher generic prices for the product’s main chemical, glyphosate, would boost ...